Long Cast Advisers Sees Pro-Dex Benefiting From Zimmer's mBos Robot Launch

Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.

Japan's Ministry of Health, Labour and Welfare revealed the findings of its annual white paper, showing that more than 70% of Japanese people have a positive attitude toward the use of advanced technologies such as artificial intelligence and robots in the medical and nursing care sectors. The online opinion survey found that 72.4% agreed or somewhat agreed with using AI to help doctors diagnose diseases, and 73.7% supported the use of robots to facilitate communication between caregivers and care recipients. At the same time, 74.5% said they felt or somewhat felt anxious about the shortage of healthcare workers, and 81.3% expressed similar concern about elderly care. The study underscores the importance of improving efficiency and raising productivity by adopting technology around 2040, when Japan's population aged 65 and over is expected to peak, amid a worsening shortage of doctors, nurses, and caregivers. The survey was conducted in January and February among people living in Japan aged 20 to 74, and received 3,000 complete responses.

Medtronic plc raised its fiscal 2027 organic revenue growth outlook to between 7.25% and 7.75%, up from previous guidance of 6.75% to 7.25%, following an impressive first quarter. CEO Geoff Martha pointed to ongoing strength in core segments including Cranial and Spinal Technologies, Surgical, and Cardiac Rhythm Management, alongside momentum in high-growth bets such as Hugo robotic surgery, Symplicity, Altaviva, Affera, and Stealth AXiS. The company also entered a $700 million partnership with Hong Kong-based Cornerstone Robotics that gives Medtronic distribution rights to the Sentire Surgical System, Cornerstone's robotic-assisted platform, in select markets outside the U.S. where it is approved; Sentire has received market approval in China, the European Union, and Singapore for general, gynecologic, thoracic, and urologic procedures. Medtronic's first-quarter organic revenue growth of 13.7% included a one-time benefit from an additional fiscal week that added $570 million to the topline and is not expected to recur. Hedge fund holdings in the stock rose to 67 in the second quarter of 2026 from 60 at the end of the first quarter, according to 13F filing data tracked by Insider Monkey.

Medtronic agreed a US$700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally, expanding its surgical robotics presence beyond its existing platforms into a new multi-country distribution arrangement. The deal makes Medtronic a multi-platform player alongside its own Hugo robotic-assisted surgery system, giving hospitals in Europe, China and Singapore a broader menu of robotics options at different price points. Medtronic also partnered with Sonus Microsystems on AI-powered wearable ultrasound technology for maternal health programs in Kenya. Medtronic is a US-based medical equipment group with a market value of about US$113.4b. Investors will watch how quickly the Sentire and Hugo systems translate into procedure volumes and installed bases in Europe, China and Singapore over the next 12 to 24 months, along with study milestones from the Kenya maternal health program, particularly data readouts on preeclampsia screening performance.

The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, a 15.1% compound annual growth rate, according to a new report added to ResearchAndMarkets.com. Robotic systems are expected to account for the largest share of the market by product and service, while surgical robotic systems, which led by type in 2025, are expected to see significant growth as surgical volumes rise. Ambulatory surgery centers are projected to register the highest end-user growth rate, and Asia Pacific is positioned as the fastest-growing regional market. Key players profiled include Intuitive Surgical, Stryker, Medtronic, and Johnson & Johnson. The report notes that high system and maintenance costs, stringent regulatory requirements, and specialized training needs may limit adoption.